Drug Discovery World

AUGUST 9, 2022

Cypex’s products are produced using a patented technology, which was developed by the University of Dundee in partnership with several leading international pharmaceutical companies. This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.? .

In-Vitro 52

In-Vitro Protein Production Bacteria 52

Drug Discovery World

SEPTEMBER 28, 2023

Earlier this year, we explored the microbiome and its role in drug development across various therapeutic areas. This is likely in part because their byproduct, lactic acid, is known to inhibit pathogenic bacteria 25. This article will focus on one such area of great unmet need and promise: women’s health.

Clinical Trials 65

Clinical Trials Clinical Trials Regulation Bacteria 65

XTalks

AUGUST 9, 2023

a leader in developing therapeutic solutions for common diseases with limited treatment alternatives, has secured approval from the US Food and Drug Administration (FDA) for its drug, Xdemvy (lotilaner ophthalmic solution) 0.25%. California-based Tarsus Pharmaceuticals Inc., What Is Demodex Blepharitis? Collarettes were identified in 69.1

FDA Approval 98

FDA Approval In-Vitro Trials Bacteria 98

XTalks

NOVEMBER 4, 2020

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. They reported their findings last week in the journal Science.

Allergies 98

Allergies Antibody In-Vitro Development 98

The Pharma Data

APRIL 28, 2021

a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.

Clinical Trials 40

Clinical Trials Clinical Trials Containment In-Vitro 40

The Pharma Data

OCTOBER 22, 2020

The Company intends to use the net proceeds from this offering to support its planned New Drug Application submission for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with quinolone-resistant pathogens, the continued clinical development of sulopenem, and for working capital and general corporate purposes.

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Sales 40

Roots Analysis

OCTOBER 16, 2023

These clones can be manipulated and mutated in vitro to alter the expression and function of a protein. These clones can be manipulated and mutated in vitro to alter the expression and function of a protein. There are some motifs, such as hairpin loops which hinder the usability of a gene.

DNA 40

DNA Gene Protein In-Vitro 40